Roche Multiple Sclerosis Drug Meets Main Goals in Two Late-Stage Trials

Roche's drug Fenebrutinib has successfully met its primary goals in two late-stage trials aimed at treating two distinct forms of multiple sclerosis. This development marks a significant milestone in the ongoing research and treatment options for this chronic disease, which affects the central nervous system and can lead to severe disability. The trials were conducted to evaluate the drug's effectiveness and safety, contributing to the understanding of multiple sclerosis therapies.